10 thoughts on “D89 – Merritt

  1. If you could use Myricetin along with Coltracene, how do you stop the toxic effects of coltracene to humans even if it is at a lower dose?

    1. Hi! The idea is that we would be using colchicine at such a low dose that it wouldn’t have any toxic side effects to humans at all. If any toxicities were to prove present, we wouldn’t be able to use this treatment.

  2. Do you think the drug that was too toxic can be a part of a cocktail with other therapeutics to help treat cancer? What are some drug characteristics you think are imperative to attack cancerous cells?

    1. The drug that was too toxic, colchicine, could potentially be part of a cocktail with other chemotherapeutics to help treat cancer if those other chemotherapeutics slightly inhibited the effect of the colchicine. They would have to reduce its effect to the point where it wouldn’t harm humans but keep it effective enough to kill cancer cells, and I think this would be hard to do, which is why we went from the angle of working on helping cells retain a lower dose of it rather than using it in combination with other therapeutics.

      Some drug characteristics I think are imperative to attack cancerous cells are the ability to stop the cell cycle before mitosis (so that the cell can’t get to the point of replication and grow the tumor) which is usually found in drugs such as chemotherapeutics that work to destroy DNA, or in the form of radiation that creates free radicals to attack DNA. I think drugs should be able to work against growth factor promotion, inhibit cell mobility (to prevent metastasis), and prevent the cell from being absorbed into the bloodstream to be transported to other parts of the body.

  3. Hey! Amazing presentation! This is a bit of a question on the background, but how has chemo become slightly ineffective?

    1. Hi! Thank you! Chemo has become slightly ineffective over time as tumors are becoming more heterogeneous. This meaning that each individual tumor stems from a myriad of mutations that accumulate over time and that current chemotherapeutics often can’t account for the differences between every cell that comprises a tumor.

  4. How might metabolical differences between humans and the model organism flies impact the effectiveness of these chemicals?

    1. Whichever organism has a set of cells with typically higher metabolic rates will process the chemicals at a higher rate; the reason we use the model organism we did is because they hit a point of their life cycle (the third instar larvae stage) where their cell processes very similarly mimic head and neck tumors, so there shouldn’t be a significant amount of metabolical discrepancies between human head and neck cancer cells and the cells of D. melanogaster.

  5. Great presentation Maddy! Were you able to determine if Myricetin is additive or synergistic?

    1. Thank you! We were not able to determine if Myricetin is additive or synergistic because none of our percent survival values were low enough to quantify any of our data as a hit; however, from what I noticed on our graphs, I would say that the effect of Myricetin in combination with colchicine was additive because it did seem to decrease the percent survival of the flies compared to the trials of the same concentrations of colchicine on its own but not necessarily exponentially.

Leave a Reply